(Reuters) — New diabetes and weight-loss medication could gain advantage sufferers present process hip substitute, with out including to complication dangers, consistent with initial information launched on Monday at a big assembly of orthopedic surgeons.In a single learn about reviewing use of Ozempic — the logo identify for Novo Nordisk’s semaglutide prescribed for hard-to-control diabetes — the drug used to be related to 44% decrease odds of growing an an infection of the newly implanted joint, after different possibility elements have been taken under consideration, researchers stated. Semaglutide is bought below the identify Wegovy for weight-loss.The ones taking Ozempic additionally had 32% decrease odds of wanting to be readmitted to the sanatorium, with out a building up in possibility for postoperative headaches.For the learn about, docs at a big New York Town sanatorium reviewed information on 9,465 sufferers with diabetes who underwent general hip arthroplasty, together with 1,653 who took Ozempic.Most of the sufferers additionally had weight problems, stated learn about chief Dr. Matthew Magruder of Maimonides Scientific Heart in Brooklyn, New York.A 2nd learn about provides to proof that semaglutide is protected for sufferers present process hip substitute. Researchers analyzed postoperative complication charges in 1,232 sufferers with weight problems who underwent general hip substitute, part of whom have been prescribed Wegovy. The 2 teams have been intently matched in age, weight and possibility elements.Ozempic manufactured by way of Novo Nordisk in a Polish pharmacy. (Jakub Porzycki/NurPhoto by way of Getty Photographs) (NurPhoto by way of Getty Photographs)Use of Wegovy didn’t building up sufferers’ dangers for postoperative issues similar to an infection or dislocation of the hip implant, want for reoperation, lung or center headaches or loss of life, researchers discovered.It isn’t transparent from the 2 research how lengthy sufferers have been taking Ozempic or Wegovy sooner than surgical operation.Neither learn about had business investment.And neither one proves semaglutide or different medication belonging to a category referred to as GLP-1 agonists are protected or protecting amongst those sufferers.“Presently, we do not need sufficient proof to surely counsel beginning GLP-1 agonists like semaglutide previous to general hip substitute,” Magruder stated. “We want top quality, potential, randomized managed trials to definitively make that advice.”(Reporting by way of Nancy Lapid; enhancing by way of Michele Gershberg and Cynthia Osterman)
